Kenneth Moch joins the OncoSpherix team as Special Advisor to the CEO: “It is a privilege to have Ken Moch serve as my advisor as we build OncoSpherix into a successful drug development company that is advancing agents that should benefit patients with many types of advanced cancer” stated Dr. Margaret K. Offermann, CEO of OncoSpherix. “He has been a trusted advisor to me since the founding of OncoSpherix, so I’m delighted that he has agreed to continue in a more formal capacity”. Mr. Kenneth Moch has more than 35 years of experience in managing and financing biomedical technologies and has played a key role in building five life science companies. From October 2016 until March, 2020, Mr. Moch has served as the president and chief executive officer of Cognition Therapeutics, Inc. He previously was the managing partner of The Salutramed Group, LLC, from September 2015 until October 2016, where he provided strategic and tactical counsel to the biotechnology and pharmaceutical industries. Prior to that, he served as president of Euclidian Life Sciences Advisors, a strategic advisory firm for life sciences companies, from April 2014 until September 2015. From April 2010 to April 2014, he served as president and chief executive officer, and as a director, of Chimerix, Inc., having joined the company as chief operating officer in June 2009. Previously, he was president and chief executive officer of three life science companies—BioMedical Enterprises, Inc., Alteon, Inc., and Biocyte Corporation—and was a co-founder and vice president of The Liposome Company, Inc. He also served as managing director of Healthcare Investment Banking at ThinkEquity Partners and as a management consultant with McKinsey & Company. In the public policy arena, Mr. Moch was a member of the board of the Biotechnology Innovation Organization, serving as chair of the Bioethics Committee, and previously served as chairman of BioNJ. Mr. Moch holds an A.B. in Biochemistry from Princeton University and an M.B.A. with emphasis in Finance and Marketing from the Stanford Graduate School of Business. With more than 25 years of experience in the biomedical technology and pharmaceutical industries, Mr. Moch brings valuable expertise in biomedical technology company leadership and financing matters.
